Comprehensive genetic dissection of the hemocyte immune response in the malaria mosquito Anopheles gambiae.

Reverse genetics in the mosquito Anopheles gambiae by RNAi mediated gene silencing has led in recent years to an advanced understanding of the mosquito immune response against infections with bacteria and malaria parasites. We developed RNAi screens in An. gambiae hemocyte-like cells using a library of double-stranded RNAs targeting 109 genes expressed highly or specifically in mosquito hemocytes to identify novel regulators of the hemocyte immune response. Assays included phagocytosis of bacterial bioparticles, expression of the antimicrobial peptide CEC1, and basal and induced expression of the mosquito complement factor LRIM1. A cell viability screen was also carried out to assess dsRNA cytotoxicity and to identify genes involved in cell growth and survival. Our results identify 22 novel immune regulators, including proteins putatively involved in phagosome assembly and maturation (Ca²âº channel, v-ATPase and cyclin-dependent protein kinase), pattern recognition (fibrinogen-domain lectins and Nimrod), immune modulation (peptidase and serine protease homolog), immune signaling (Eiger and LPS-induced factor), cell adhesion and communication (Laminin B1 and Ninjurin) and immune homeostasis (Lipophorin receptor). The development of robust functional cell-based assays paves the way for genome-wide functional screens to study the mosquito immune response to infections with human pathogens.

Affordability assessment of passive retrofitting measures for residential buildings using life cycle assessment.

Climate change impacts have been increasingly noticeable worldwide, especially as energy concerns have increased. Because buildings consume significant amounts of energy, sustainably retrofitting existing buildings has become essential. However, several countries are pretty concerned about the affordability of retrofitting and energy conservation measures. Therefore, this research assesses the affordability of selected passive heating and cooling retrofitting strategies using the residual approach methodology. Specifically, this work studies the effects and efficiency of retrofitting the residential buildings in Irbid, Jordan, through life cycle analysis, where dynamic thermal simulation (IES-VE) is employed. This strategy determines the required heating and cooling loads, the life cycle carbon dioxide emissions, and the economic feasibility of retrofitting using the Net Present Value methodology. The results show that passive building retrofitting can generate considerable economic and environmental benefits. Additionally, the affordability assessment reveals that retrofitting measures are affordable for 73-78% of Jordanian households. Furthermore, retrofitting makes the energy required for building conditioning affordable for 82.8-85.8% of households. This affordability assessment proved that the initial investment cost of retrofitting is the major obstacle to implementing it, especially for low-income households, despite the long-term economic and environmental benefits of this process. Thus, governmental financial support for the retrofitting projects would support achieving the sustainable development goals and mitigating climate change impacts.

Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.

PURPOSE: The Wilms' tumor antigen (WT1) is overexpressed in approximately 90% of breast tumors and, thus, is a potential target antigen for the immunotherapy of breast cancer. We have tested the working hypotheses that WT1 can be immunogenic in patients with breast cancer and can stimulate CTL of sufficient avidity to kill tumor cells. EXPERIMENTAL DESIGN: Paired tumor-draining lymph node and peripheral blood samples were analyzed from five HLA-A2-positive patients with stage I/II breast cancer. Fluorescent HLA-A*0201/WT1 tetramers were used to quantify WT1-specific CTL and the functional capacity of the CTL was assessed using cytotoxicity assays and intracellular cytokine staining. RESULTS: WT1 tetramer-binding T cells expanded from all lymph node samples but none of the corresponding peripheral blood samples. Functional assays were carried out on T cells from the patient who had yielded the highest frequency of HLA-A*0201/WT1 tetramer-positive cells. The cytotoxicity assays showed WT1 peptide--specific killing activity of the CTL, whereas intracellular cytokine staining confirmed that the tetramer--positive T cells produced IFN-gamma after stimulation with WT1 peptide. These WT1-specific T cells killed HLA-A2-positive breast cancer cell lines treated with IFN-gamma but no killing was observed with untreated tumor cells. CONCLUSIONS: These results show that WT1-specific CTL can be expanded from the tumor-draining lymph nodes of breast cancer patients and that they can display peptide-specific effector function. However, the CTL only killed IFN-gamma-treated tumor targets expressing high levels of HLA-A2 and not tumor cells with low HLA expression. This suggests that induction of autologous WT1-specific CTL may offer only limited tumor protection and that strategies that allow a high level of peptide/MHC complex presentation and/or improve CTL avidity may be required.

Dendritic cell immunization induces Nonprotective WT1-specific CTL responses in mouse.

In the present article we describe the immunogenicity in the mouse of 2 epitopes from the tumor-associated antigen Wilms tumor 1 antigen (WT1). The newly described K-restricted pWT330 epitope stimulates high-avidity allo-major histocompatibility complex restricted cytotoxic T lymphocyte (CTL) capable of killing WT1-expressing tumor cell lines. The epitope pWT126 has been previously described as a D-restricted CTL epitope. Both epitopes are weakly immunogenic as immunization with incomplete Freund adjuvant induced poor CTL responses. In contrast, when coated onto dendritic cells (DCs) both peptides readily induced CTL responses. However, these peptide-specific CTL were of low avidity and unable to recognize WT1-expressing tumor cells in vitro and to protect against tumor challenge in vivo. In contrast, vaccination with DCs coated with peptides derived from the nonself antigen ovalbumin (OVA) induced CTL that recognized OVA-expressing tumor cells and protected against tumor growth in vivo. These data show that although DC vaccination readily stimulated CTL against WT1 peptides, these CTL did not display antitumor activity in vitro and in vivo. This suggests that tolerance to the 2 WT1 epitopes interferes with the generation of protective CTL immunity in mice.

Incomplete tolerance to the tumour-associated antigen MDM2.

MDM2 is a tumour-associated antigen widely expressed by normal tissues and over-expressed by many tumours of different origin. We wanted to define the level of immunological tolerance against MDM2 and explore its potential in tumour immunotherapy. Two murine MDM2 epitopes, pMDM100 and pMDM441, differ in their affinity for MHC class I molecules. Previous observations made in vitro suggested that pMDM100, due to its high affinity for K(b), induces a high level of tolerance, whereas tolerance to pMDM441, which binds poorly to D(b), is incomplete. In the present article we test the immunogenicity of these two peptides in vivo. Surprisingly, mice immunized with pMDM100 generated cytotoxic T lymphocytes (CTL) that killed tumour cell lines expressing MDM2 endogenously, indicating the existence of high-avidity CTL specific for a widely expressed protein. However, the response was limited as effector CTL disappeared after continued in vitro stimulation. While immunization with the individual MDM2 peptides did not protect against tumour challenge, mice immunized with both pMDM100 and pMDM441 were partially protected. These observations suggest that targeting of multiple epitopes may be required to vaccinate against tumours expressing elevated levels of CTL-recognized self-proteins.